3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
11
Lymphoma
9
Lymphoma, T-Cell, Cutaneous
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms, Plasma Cell
6
Myelodysplastic Syndromes
6
Lymphoma, Non-Hodgkin
6
Lymphoma, Mantle-Cell
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
6
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Myeloid, Acute
6
Leukemia, Myeloid, Accelerated Phase
6
Leukemia
6
Hodgkin Disease
6
Burkitt Lymphoma
6
Skin Neoplasms
5
Sezary Syndrome
5
Primary Myelofibrosis
5
Myeloproliferative Disorders
5
Myelodysplastic-Myeloproliferative Diseases
5
Mycosis Fungoides
5
Multiple Myeloma
5
Leukemia, Myelomonocytic, Chronic
5
Leukemia, Myeloid, Chronic-Phase
5
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
5
Graft vs Host Disease
5
Congenital Abnormalities
5
Interventions
cemiplimab
3
Transdermal Patch
1
Sirolimus
1
Prednisone
1
Everolimus
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cutaneous Squamous Cell Carcinoma
×
Sirolimus
×
Dermatologic
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts